Nurexone Biologic Inc
- LAST PRICE0.6300
- TODAY'S CHANGE (%)-0.0200 (-3.0769%)
- Bid / Lots0.6300/ 7
- Ask / Lots0.6500/ 100
- Open / Previous Close0.6400 / 0.6500
- Day Range
- 52 Week Range
- Volume6,650
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRX |
|---|---|---|
| 12:59 ET | 3500 | 0.64 |
| 01:03 ET | 1000 | 0.64 |
| 01:12 ET | 500 | 0.64 |
| 03:41 ET | 1500 | 0.63 |
Apr 25, 2024
Apr 19, 2024
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine, from 4:04PM ET on Friday Apr 19, 2024 by Dow Jones
4:04PM ET on Friday Apr 19, 2024 by Dow Jones
Apr 2, 2024
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update, from 8:31AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:31AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurexone Biologic Inc | 42.8M | -5.6x | --- |
Defence Therapeutics Inc | 56.8M | -4.0x | --- |
Satellos Bioscience Inc | 54.2M | -3.0x | --- |
Briacell Therapeutics Corp | 46.9M | -2.7x | --- |
Helix Biopharma Corp | 48.2M | -7.7x | --- |
KDA Group Inc | 70.2M | 209.0x | --- |
Company Information
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
Contact Information
- Headquarters
- 9 Mezada Street, Bsr 3 Tower, 30 FloorBNEI BRAK, Israel 5120109
- Phone
- 416-410-5297
- Fax
- 416-410-5297
Executives
- Chairman of the Board, Chief Executive Officer
- James Richardson
- Chief Financial Officer, Corporate Secretary, Director
- John Arnold
- Director
- John-Peter Bradford
- Independent Director
- Peter Andrews
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 65.8M |
Nurexone Biologic Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.11 |
Book Value | $0.01 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
